Oral Biologics Market by Therapy Type (Tumour Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, and Interleukin Inhibitors) by Indications (Arthritis, Asthma, Carcinoma, Crohn’s Disease, Diabetes, Enterocolitis, Multiple myeloma, Multiple sclerosis

Oral Biologics Market by Therapy Type (Tumour Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, and Interleukin Inhibitors) by Indications (Arthritis, Asthma, Carcinoma, Crohn’s Disease, Diabetes, Enterocolitis, Multiple myeloma, Multiple sclerosis, Psoriasis, Sarcoma, and Others) By Application (Inflammatory, Metabolic disorders, and Neoplastic) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parental route and only guanylate cyclase-c agonist class of drug is approved oral biological in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Frequent research and development activities by key players for the development of novel oral biologics products and launch them in market is expected to boost global oral biologics market growth over the forecast period.

For instance, Allena Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, is involved in development of Reloxaliase, a non-absorbed, orally-administered enzyme for treatment of hyperoxaluria. Currently (June 2019), Reloxaliase is in Phase 2 clinical trial.

Furthermore, key players in the market are involved in strategic partnership and mergers for development of novel oral biologics products and gain its approval. Such strategic partnerships are expected to drive global oral biologics market growth.

For instance, in December 2017, Rani Therapeutics and Shire Plc. collaborated to conduct research and evaluate the application of RaniPill technology for the oral delivery of factor VIII therapy for Hemophilia A patients

In January 2017, Enteris BioPharma, Inc. and Ferring Pharmaceuticals entered into license agreement to leverage Enteris proprietary oral drug delivery platform Peptelligence, to develop an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

Such strategies among key players may lead to development of novel oral biologics, which in turn is expected to drive global oral biologics market growth over the forecast period.

Key features of the study:

• This report provides in-depth analysis of global oral biologics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global oral biologics market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc. Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global oral biologics market

Detailed Segmentation:

• Global Oral Biologics Market, By Drug Class:
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• Global Oral Biologics Market, By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• Global Oral Biologics Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Oral Biologics Market, By Region:
• North America
• By Drug Class :
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.S.
• Canada
• Europe
• By Drug Class :
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Drug Class :
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• By Drug Class:
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
• By Drug Class :
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Drug Class :
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country/Region:
• Central Africa
• South Africa
• North Africa
• Company Profiles
• Novo Nordisk A/S*
• Company Overview
• Product Portfolio
• Financial Performance
• Key Strategies
• Recent Developments
• Biocon Limited
• Oramed Pharmaceuticals, Inc.
• Rani Therapeutics
• Entera Bio Ltd.
• Allergan plc.
• Emisphere Technologies, Inc.
• Enteris BioPharma, Inc.
• Chiasma, Inc.
• Allena Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.